These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26900768)

  • 1. Application of an Integrated GPCR SAR-Modeling Platform To Explain the Activation Selectivity of Human 5-HT2C over 5-HT2B.
    Heifetz A; Storer RI; McMurray G; James T; Morao I; Aldeghi M; Bodkin MJ; Biggin PC
    ACS Chem Biol; 2016 May; 11(5):1372-82. PubMed ID: 26900768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
    Green MP; McMurray G; Storer RI
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT₂C) receptor agonists with exquisite functional selectivity over 5-HT₂A and 5-HT₂B receptors.
    Storer RI; Brennan PE; Brown AD; Bungay PJ; Conlon KM; Corbett MS; DePianta RP; Fish PV; Heifetz A; Ho DK; Jessiman AS; McMurray G; de Oliveira CA; Roberts LR; Root JA; Shanmugasundaram V; Shapiro MJ; Skerten M; Westbrook D; Wheeler S; Whitlock GA; Wright J
    J Med Chem; 2014 Jun; 57(12):5258-69. PubMed ID: 24878222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors.
    Kim SK; Li Y; Abrol R; Heo J; Goddard WA
    J Chem Inf Model; 2011 Feb; 51(2):420-33. PubMed ID: 21299232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease.
    Reid TE; Kumar K; Wang XS
    Curr Top Med Chem; 2013; 13(11):1353-62. PubMed ID: 23675941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.
    Fevig JM; Feng J; Rossi KA; Miller KJ; Wu G; Hung CP; Ung T; Malmstrom SE; Zhang G; Keim WJ; Cullen MJ; Rohrbach KW; Qu Q; Gan J; Pelleymounter MA; Robl JA
    Bioorg Med Chem Lett; 2013 Jan; 23(1):330-5. PubMed ID: 23177783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT
    Zhang G; McCorvy JD; Shen S; Cheng J; Roth BL; Kozikowski AP
    Eur J Med Chem; 2019 Nov; 182():111626. PubMed ID: 31445232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.
    Brennan PE; Whitlock GA; Ho DK; Conlon K; McMurray G
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4999-5003. PubMed ID: 19646865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT
    Carpenter J; Wang Y; Wu G; Feng J; Ye XY; Morales CL; Broekema M; Rossi KA; Miller KJ; Murphy BJ; Wu G; Malmstrom SE; Azzara AV; Sher PM; Fevig JM; Alt A; Bertekap RL; Cullen MJ; Harper TM; Foster K; Luk E; Xiang Q; Grubb MF; Robl JA; Wacker DA
    J Med Chem; 2017 Jul; 60(14):6166-6190. PubMed ID: 28635286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
    Porter RH; Benwell KR; Lamb H; Malcolm CS; Allen NH; Revell DF; Adams DR; Sheardown MJ
    Br J Pharmacol; 1999 Sep; 128(1):13-20. PubMed ID: 10498829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore-directed homology modeling and molecular dynamics simulation of G protein-coupled receptor: study of possible binding modes of 5-HT2C receptor agonists.
    Zuo Z; Chen G; Luo X; Puah C; Zhu W; Chen K; Jiang H
    Acta Biochim Biophys Sin (Shanghai); 2007 Jun; 39(6):413-22. PubMed ID: 17558446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new class of 5-HT
    Casey AB; Mukherjee M; McGlynn RP; Cui M; Kohut SJ; Booth RG
    Br J Pharmacol; 2022 Jun; 179(11):2610-2630. PubMed ID: 34837227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody.
    Ishchenko A; Wacker D; Kapoor M; Zhang A; Han GW; Basu S; Patel N; Messerschmidt M; Weierstall U; Liu W; Katritch V; Roth BL; Stevens RC; Cherezov V
    Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8223-8228. PubMed ID: 28716900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
    Zhao G; Kwon C; Bisaha SN; Stein PD; Rossi KA; Cao X; Ung T; Wu G; Hung CP; Malmstrom SE; Zhang G; Qu Q; Gan J; Keim WJ; Cullen MJ; Rohrbach KW; Devenny J; Pelleymounter MA; Miller KJ; Robl JA
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3914-9. PubMed ID: 23683593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT
    Peng Y; McCorvy JD; Harpsøe K; Lansu K; Yuan S; Popov P; Qu L; Pu M; Che T; Nikolajsen LF; Huang XP; Wu Y; Shen L; Bjørn-Yoshimoto WE; Ding K; Wacker D; Han GW; Cheng J; Katritch V; Jensen AA; Hanson MA; Zhao S; Gloriam DE; Roth BL; Stevens RC; Liu ZJ
    Cell; 2018 Feb; 172(4):719-730.e14. PubMed ID: 29398112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders.
    Tye H; Mueller SG; Prestle J; Scheuerer S; Schindler M; Nosse B; Prevost N; Brown CJ; Heifetz A; Moeller C; Pedret-Dunn A; Whittaker M
    Bioorg Med Chem Lett; 2011 Jan; 21(1):34-7. PubMed ID: 21146986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.
    Canal CE; Morgan D; Felsing D; Kondabolu K; Rowland NE; Robertson KL; Sakhuja R; Booth RG
    J Pharmacol Exp Ther; 2014 May; 349(2):310-8. PubMed ID: 24563531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Alkyl-4-aryl-pyrimidine fused heterocycles as selective 5-HT2A antagonists.
    Shireman BT; Dvorak CA; Rudolph DA; Bonaventure P; Nepomuceno D; Dvorak L; Miller KL; Lovenberg TW; Carruthers NI
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2103-8. PubMed ID: 18282705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.